1832 Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.55M | Sell |
2,000
-214,864
| -99% | -$164M | ﹤0.01% | 525 |
|
|
2025
Q4 | $167M | Buy |
+216,864
| New | +$147M | 0.13% | 112 |
|
|
2025
Q2 | – | Sell |
-2,092
| Closed | -$1.33M | – | 746 |
|
|
2025
Q1 | $1.33M | Sell |
2,092
-2,695
| -56% | -$1.85M | ﹤0.01% | 541 |
|
|
2024
Q4 | $3.41M | Buy |
4,787
+871
| +22% | +$731K | ﹤0.01% | 408 |
|
|
2024
Q3 | $4.12M | Buy |
3,916
+1,731
| +79% | +$1.93M | ﹤0.01% | 422 |
|
|
2024
Q2 | $2.3M | Sell |
2,185
-621
| -22% | -$602K | ﹤0.01% | 480 |
|
|
2024
Q1 | $2.7M | Buy |
2,806
+552
| +24% | +$525K | ﹤0.01% | 450 |
|
|
2023
Q4 | $1.98M | Buy |
2,254
+353
| +19% | +$291K | ﹤0.01% | 489 |
|
|
2023
Q3 | $1.56M | Sell |
1,901
-314
| -14% | -$247K | ﹤0.01% | 523 |
|
|
2023
Q2 | $1.59M | Sell |
2,215
-6,679
| -75% | -$5.15M | ﹤0.01% | 526 |
|
|
2023
Q1 | $7.31M | Buy |
8,894
+5,908
| +198% | +$4.46M | 0.01% | 382 |
|
|
2022
Q4 | $2.15M | Sell |
2,986
-653
| -18% | -$482K | ﹤0.01% | 513 |
|
|
2022
Q3 | $2.51M | Sell |
3,639
-645
| -15% | -$406K | ﹤0.01% | 484 |
|
|
2022
Q2 | $2.53M | Buy |
4,284
+940
| +28% | +$611K | ﹤0.01% | 484 |
|
|
2022
Q1 | $2.3M | Buy |
+3,344
| New | +$2.12M | ﹤0.01% | 529 |
|
|
2021
Q4 | – | Sell |
-718
| Closed | -$438K | – | 844 |
|
|
2021
Q3 | $438K | Buy |
+718
| New | +$446K | ﹤0.01% | 562 |
|
|
2021
Q1 | – | Sell |
-5,100
| Closed | -$2.45M | – | 768 |
|
|
2020
Q4 | $2.45M | Hold |
5,100
| – | – | 0.01% | 427 |
|
|
2020
Q3 | $2.95M | Sell |
5,100
-25,200
| -83% | -$15.3M | 0.01% | 386 |
|
|
2020
Q2 | $18.7M | Buy |
+30,300
| New | +$17.2M | 0.06% | 197 |
|
|
2020
Q1 | – | Sell |
-66
| Closed | -$25K | – | 745 |
|
|
2019
Q4 | $25K | Hold |
66
| – | – | ﹤0.01% | 584 |
|
|
2019
Q3 | $18K | Hold |
66
| – | – | ﹤0.01% | 612 |
|
|
2019
Q2 | $21K | Sell |
66
-4
| -6% | -$1.33K | ﹤0.01% | 612 |
|
|
2019
Q1 | $29K | Hold |
70
| – | – | ﹤0.01% | 535 |
|
|
2018
Q4 | $26K | Sell |
70
-1
| -1% | -$366 | ﹤0.01% | 517 |
|
|
2018
Q3 | $29K | Buy |
71
+9
| +15% | +$3.42K | ﹤0.01% | 566 |
|
|
2018
Q2 | $23K | Buy |
62
+31
| +100% | +$9.7K | ﹤0.01% | 543 |
|
|
2018
Q1 | $11K | Buy |
+31
| New | +$10.8K | ﹤0.01% | 603 |
|
|
2016
Q2 | – | Sell |
-4,800
| Closed | -$2.91M | – | 729 |
|
|
2016
Q1 | $2.91M | Sell |
4,800
-179,430
| -97% | -$73.9M | 0.01% | 360 |
|
|
2015
Q4 | $99M | Sell |
184,230
-6,540
| -3% | -$3.54M | 0.43% | 68 |
|
|
2015
Q3 | $87.2M | Sell |
190,770
-32,769
| -15% | -$17.6M | 0.36% | 72 |
|
|
2015
Q2 | $112M | Buy |
223,539
+219,169
| +5,015% | +$107M | 0.38% | 71 |
|
|
2015
Q1 | $1.98M | Sell |
4,370
-114,210
| -96% | -$48.4M | 0.01% | 370 |
|
|
2014
Q4 | $47.9M | Sell |
118,580
-117,010
| -50% | -$46M | 0.15% | 136 |
|
|
2014
Q3 | $84.2M | Buy |
235,590
+228,350
| +3,154% | +$76.5M | 0.27% | 96 |
|
|
2014
Q2 | $2.05M | Sell |
7,240
-333,000
| -98% | -$98.7M | 0.01% | 423 |
|
|
2014
Q1 | $101M | Sell |
340,240
-24,730
| -7% | -$7.62M | 0.35% | 81 |
|
|
2013
Q4 | $100M | Buy |
364,970
+92,800
| +34% | +$26.7M | 0.38% | 68 |
|
|
2013
Q3 | $84.8M | Sell |
272,170
-240,850
| -47% | -$63.4M | 0.38% | 72 |
|
|
2013
Q2 | $115M | Buy |
+513,020
| New | +$119M | 0.5% | 53 |
|
Other funds holding REGN
VCM
N
1832 Asset Management's REGN Position: Q1 2026 in Review
1832 Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 99% in Q1 2026, selling an estimated $164M and leaving 2,000 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #525.
1832 Asset Management first reported a position in REGN in Q2 2013 and has held it in 39 quarters since. The position peaked at $167M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- 1832 Asset Management held 2,000 shares of Regeneron Pharmaceuticals worth $1.55M as of Q1 2026.
- 1832 Asset Management sold 214,864 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $164M.
- Regeneron Pharmaceuticals made up ﹤0.01% of 1832 Asset Management's portfolio in Q1 2026, its #525 holding.
- 1832 Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
- 1832 Asset Management's Regeneron Pharmaceuticals position peaked at $167M in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.